Lenabasum
Lenabasum is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cannabinoid receptor 2 and cannabinoid receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | — | 2 | 1 | — | 3 | 5 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | 1 | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 2 | — | — | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | 1 | — | — | 2 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | 1 | — | — | 2 |
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | 1 | 2 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | 2 | — | — | — | 2 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 2 | — | — | — | 2 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | 1 | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Show 19 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 4 | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 4 | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | — | — | 2 | 2 |
| Uterine cervical neoplasms | D002583 | — | — | — | — | — | — | 1 | 1 |
| Mass screening | D008403 | — | — | — | — | — | — | 1 | 1 |
| Four-dimensional computed tomography | D056973 | — | — | — | — | — | — | 1 | 1 |
| Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | — | — | — | 1 | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lenabasum |
| INN | lenabasum |
| Description | Lenabasum (also known as ajulemic acid, 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab) is a synthetic cannabinoid that shows anti-fibrotic and anti-inflammatory effects in pre-clinical studies without causing a subjective "high". Although its design was inspired by a metabolite of delta-9-THC known as delta-9-THC-11-oic acid, lenabasum is an analog of the delta-8-THC metabolite delta-8-THC-11-oic acid. It is being developed for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis. It does not share the anti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve. Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of the CB2 receptor leading to production of specialized proresolving eicosanoids such as lipoxin A4 and prostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced by tetrahydrocannabinol. Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases. Development since been discontinued.
|
| Classification | Small molecule |
| Drug class | cannabinol derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C(=O)O)C[C@@H]21 |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL456341 |
| ChEBI ID | — |
| PubChem CID | 3083542 |
| DrugBank | — |
| UNII ID | OGN7X90BT8 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,099 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
36 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use